Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 11

1.

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators.

Mov Disord. 2014 Apr;29(4):470-8. doi: 10.1002/mds.25824. Epub 2014 Feb 14.

PMID:
24532007
2.

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T; TAUROS MRI Investigators.

Mov Disord. 2014 Apr;29(4):479-87. doi: 10.1002/mds.25815. Epub 2014 Jan 31.

PMID:
24488721
3.

Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian cohorts.

Cubo E, Doumbe J, Martinez-Martin P, Rodriguez-Blazquez C, Kuate C, Mariscal N, Lopez I, Noubissi G, Mapoure YN, Jon JL, Mbahe S, Tchaleu B, Catalan MJ; ELEP Group.

J Neurol Sci. 2014 Jan 15;336(1-2):122-6. doi: 10.1016/j.jns.2013.10.021. Epub 2013 Oct 22.

PMID:
24183853
4.

Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease.

Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P; ELEP Group.

Parkinsonism Relat Disord. 2013 Dec;19(12):1152-5. doi: 10.1016/j.parkreldis.2013.07.026. Epub 2013 Aug 15.

PMID:
23953775
5.

Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease.

Cubo E, Martín PM, Martin-Gonzalez JA, Rodríguez-Blázquez C, Kulisevsky J; ELEP Group Members.

Mov Disord. 2010 Jan 15;25(1):70-5. doi: 10.1002/mds.22896.

PMID:
20014110
6.

What contributes to driving ability in Parkinson's disease.

Cubo E, Martinez Martin P, Gonzalez M, Bergareche A, Campos V, Fernández JM, Alvárez M, Bayes A; Elep Group.

Disabil Rehabil. 2010;32(5):374-8. doi: 10.3109/09638280903168507.

PMID:
19958153
7.

Assessing autonomic symptoms of Parkinson's disease with the SCOPA-AUT: a new perspective from Rasch analysis.

Forjaz MJ, Ayala A, Rodriguez-Blazquez C, Frades-Payo B, Martinez-Martin P; Longitudinal Parkinson's Disease Patient Study, Estudio longitudinal de pacientes con enferedad de Parkinson- ELEP Group.

Eur J Neurol. 2010 Feb;17(2):273-9. doi: 10.1111/j.1468-1331.2009.02835.x. Epub 2009 Nov 12.

PMID:
19912321
8.

Should the SCOPA-COG be modified? A Rasch analysis perspective.

Forjaz MJ, Frades-Payo B, Rodriguez-Blazquez C, Ayala A, Martinez-Martin P; Longitudinal Parkinson's Disease Patient Study, Estudio longitudinal de pacients con enfermedad da Parkinson Group.

Eur J Neurol. 2010 Feb;17(2):202-7. doi: 10.1111/j.1468-1331.2009.02791.x. Epub 2009 Oct 14.

PMID:
19832901
9.

Independent validation of the scales for outcomes in Parkinson's disease-autonomic (SCOPA-AUT).

Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, de Pedro-Cuesta J, Martinez-Martin P; Longitudinal Parkinson's Disease Patient Study, Estudio Longitudinal de Pacients con Enfermedad da Parkinson Group.

Eur J Neurol. 2010 Feb;17(2):194-201. doi: 10.1111/j.1468-1331.2009.02788.x. Epub 2009 Sep 23.

PMID:
19780808
10.

Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease.

Rodriguez-Blazquez C, Frades-Payo B, Forjaz MJ, de Pedro-Cuesta J, Martinez-Martin P; Longitudinal Parkinson's Disease Patient Study Group.

Mov Disord. 2009 Mar 15;24(4):519-25. doi: 10.1002/mds.22321.

PMID:
19177496
11.

Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease.

Forjaz MJ, Rodriguez-Blázquez C, Martinez-Martin P; Longitudinal Parkinson's Disease Patient Study Group.

Mov Disord. 2009 Mar 15;24(4):526-32. doi: 10.1002/mds.22409.

PMID:
19097178
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk